Literature DB >> 26966014

Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy.

Zhi Qiang Huang1, Milan Raska1,2, Tyler J Stewart1, Colin Reily1, R Glenn King1, David K Crossman1, Michael R Crowley1, Audra Hargett1, Zhixin Zhang3,4, Hitoshi Suzuki1,5, Stacy Hall1, Robert J Wyatt6, Bruce A Julian1, Matthew B Renfrow1, Ali G Gharavi7, Jan Novak8.   

Abstract

Autoantibodies against galactose-deficient IgA1 drive formation of pathogenic immune complexes in IgA nephropathy. IgG autoantibodies against galactose-deficient IgA1 in patients with IgA nephropathy have a specific amino-acid sequence, Y1CS3, in the complementarity-determining region 3 of the heavy chain variable region compared with a Y1CA3 sequence in similar isotype-matched IgG from healthy controls. We previously found that the S3 residue is critical for binding galactose-deficient IgA1. To determine whether this difference is due to a rare germline sequence, we amplified and sequenced the corresponding germline variable region genes from peripheral blood mononuclear cells of seven patients with IgA nephropathy and six healthy controls from whom we had cloned single-cell lines secreting monoclonal IgG specific for galactose-deficient IgA1. Sanger DNA sequencing revealed that complementarity-determining region 3 in the variable region of the germline genes encoded the Y1C(A/V)3 amino-acid sequence. Thus, the A/V>S substitution in the complementarity-determining region 3 of anti-galactose-deficient-IgA1 autoantibodies of the patients with IgA nephropathy is not a rare germline gene variant. Modeling analyses indicated that the S3 hydroxyl group spans the complementarity-determining region 3 loop stem, stabilizing the adjacent β-sheet and stem structure, important features for effective binding to galactose-deficient IgA1. Understanding processes leading to production of the autoantibodies may offer new approaches to treat IgA nephropathy.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  IgA nephropathy; immune complexes; immunology

Mesh:

Substances:

Year:  2016        PMID: 26966014      PMCID: PMC5084875          DOI: 10.1681/ASN.2014101044

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  29 in total

Review 1.  B cells in autoimmune diseases: insights from analyses of immunoglobulin variable (Ig V) gene usage.

Authors:  Angela Lee Foreman; Judy Van de Water; Marie-Lise Gougeon; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2007-01-12       Impact factor: 9.754

Review 2.  IgA nephropathy.

Authors:  Robert J Wyatt; Bruce A Julian
Journal:  N Engl J Med       Date:  2013-06-20       Impact factor: 91.245

3.  The testosterone binding mechanism of an antibody derived from a naïve human scFv library.

Authors:  Merja H Niemi; Kristiina Takkinen; Lotta K Amundsen; Hans Söderlund; Juha Rouvinen; Matti Höyhtyä
Journal:  J Mol Recognit       Date:  2011 Mar-Apr       Impact factor: 2.137

Review 4.  Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies.

Authors:  Krzysztof Kiryluk; Jan Novak; Ali G Gharavi
Journal:  Annu Rev Med       Date:  2012-10-16       Impact factor: 13.739

Review 5.  Glycosylation of IgA1 and pathogenesis of IgA nephropathy.

Authors:  Jan Novak; Bruce A Julian; Jiri Mestecky; Matthew B Renfrow
Journal:  Semin Immunopathol       Date:  2012-03-21       Impact factor: 9.623

Review 6.  Preventing AID, a physiological mutator, from deleterious activation: regulation of the genomic instability that is associated with antibody diversity.

Authors:  Hitoshi Nagaoka; Thinh Huy Tran; Maki Kobayashi; Masatoshi Aida; Tasuku Honjo
Journal:  Int Immunol       Date:  2010-03-05       Impact factor: 4.823

Review 7.  The pathogenesis of IgA nephropathy.

Authors:  Richard J Glassock
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-03       Impact factor: 2.894

8.  Two levels of protection for the B cell genome during somatic hypermutation.

Authors:  Man Liu; Jamie L Duke; Daniel J Richter; Carola G Vinuesa; Christopher C Goodnow; Steven H Kleinstein; David G Schatz
Journal:  Nature       Date:  2008-02-14       Impact factor: 49.962

Review 9.  Transcription as a source of genome instability.

Authors:  Nayun Kim; Sue Jinks-Robertson
Journal:  Nat Rev Genet       Date:  2012-02-14       Impact factor: 53.242

10.  The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus.

Authors:  F Matsuda; K Ishii; P Bourvagnet; K i Kuma; H Hayashida; T Miyata; T Honjo
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more
  13 in total

Review 1.  IgA Nephropathy.

Authors:  Jennifer C Rodrigues; Mark Haas; Heather N Reich
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 8.237

Review 2.  [Pathophysiology and treatment of IgA nephropathy].

Authors:  R Bollin; H Haller
Journal:  Internist (Berl)       Date:  2018-07       Impact factor: 0.743

3.  Galactosylation of IgA1 Is Associated with Common Variation in C1GALT1.

Authors:  Daniel P Gale; Karen Molyneux; David Wimbury; Patricia Higgins; Adam P Levine; Ben Caplin; Anna Ferlin; Peiran Yin; Christopher P Nelson; Horia Stanescu; Nilesh J Samani; Robert Kleta; Xueqing Yu; Jonathan Barratt
Journal:  J Am Soc Nephrol       Date:  2017-02-16       Impact factor: 10.121

4.  Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy.

Authors:  Zina Moldoveanu; Hitoshi Suzuki; Colin Reily; Kenji Satake; Lea Novak; Nuo Xu; Zhi-Qiang Huang; Barbora Knoppova; Atlas Khan; Stacy Hall; Hiroyuki Yanagawa; Rhubell Brown; Colleen J Winstead; Darrell B O'Quinn; Amy Weinmann; Ali G Gharavi; Krzysztof Kiryluk; Bruce A Julian; Casey T Weaver; Yusuke Suzuki; Jan Novak
Journal:  J Autoimmun       Date:  2021-01-25       Impact factor: 7.094

Review 5.  IgA glycosylation and immune complex formation in IgAN.

Authors:  Hitoshi Suzuki; Jan Novak
Journal:  Semin Immunopathol       Date:  2021-09-27       Impact factor: 9.623

Review 6.  IgA vasculitis with nephritis: update of pathogenesis with clinical implications.

Authors:  M Colleen Hastings; Dana V Rizk; Krzysztof Kiryluk; Raoul Nelson; Rima S Zahr; Jan Novak; Robert J Wyatt
Journal:  Pediatr Nephrol       Date:  2021-04-05       Impact factor: 3.651

7.  Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?

Authors:  Hitoshi Suzuki; Landino Allegri; Yusuke Suzuki; Stacy Hall; Zina Moldoveanu; Robert J Wyatt; Jan Novak; Bruce A Julian
Journal:  Dis Markers       Date:  2016-08-28       Impact factor: 3.434

8.  Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy.

Authors:  William J Placzek; Hiroyuki Yanagawa; Yuko Makita; Matthew B Renfrow; Bruce A Julian; Dana V Rizk; Yusuke Suzuki; Jan Novak; Hitoshi Suzuki
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

Review 9.  New insights into the pathogenesis of IgA nephropathy.

Authors:  See Cheng Yeo; Chee Kay Cheung; Jonathan Barratt
Journal:  Pediatr Nephrol       Date:  2017-06-17       Impact factor: 3.714

Review 10.  The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.

Authors:  Barbora Knoppova; Colin Reily; Nicolas Maillard; Dana V Rizk; Zina Moldoveanu; Jiri Mestecky; Milan Raska; Matthew B Renfrow; Bruce A Julian; Jan Novak
Journal:  Front Immunol       Date:  2016-04-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.